Skip to main content
ISTH 2024 Main banner
Back

Bernd Jilma, MD

Professor
Department of Clinical Pharmacology, Medical University Vienna
Vienna, Wien, Austria

For more than 30 years Dr. Jilma has worked in the field of clinical pharmacology. Dr. Jilma served on various regulatory committees of the European Medicines Agency. (COMP, CAT, SAWP). His early research career focused on evaluating anticoagulants in endotoxemia driven coagulation. Dr. Jilma identified potentially detrimental drug interactions of morphine and platelet function inhibitors. Early clinical phase I/II trials with an aptamer directed against von Willebrand factor provided proof of concept for the treatment of thrombotic thrombocytopenic purpura. On the hand, this encouraged further development of a biological directed against the same target, which eventually led to the marketing approval of caplacizumab. On the other hand it led to develoment of rondaptivon pegol (BT200) for the treatment of von Willebrand Disease. Dr. Jilma also designed and served as a principal investigator of the phase I-III trials, which led to marketing authorization of the C1s complement inhibitor sutimlimab.

Presentation(s):